Company: RGNT
Filing Date: 2025-05-19
Form Type: F-1/A
Source: 0001213900-25-045479
Chunk: 18

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-19
Form: F-1/A
Chunk 18
---
 as of such date, at an exercise price of $3.97, of which 79,290 were vested as of such date; |

| ● | 465,533 Ordinary Shares                                                                                                           
 issuable upon the exercise of options to be issued to the Chairman of our board of directors upon the completion of this offering 
 under our incentive option plan, at an exercise price of NIS 0.04;                                                                |

| ● | 191,473 Ordinary Shares                                                                                                            
 issuable upon the exercise of options to be issued to consultants and certain investors upon the completion of this offering under 
 our incentive option plan, at an exercise price of NIS 0.004;                                                                      |

| ● | Ordinary Shares underlying                                                                                                            
 warrants issuable to the Bridge Loan lenders to purchase such number of Ordinary Shares equal to two times the respective loan amount 
 of each Bridge Loan due to such lenders, based on a price per share equal to 75% of the lowest price per Ordinary Share during the    
 first five trading days following the consummation of this offering;                                                                  |

| ● | Ordinary Shares underlying                                                                                                            
 warrants issuable to the 2024 Loan Agreements lenders to purchase such number of Ordinary Shares equal to two times the respective    
 loan amount of each 2024 Loan Agreement due to such lenders, based on a price per share equal to 75% of the lowest price per Ordinary 
 Share during the first five trading days following the consummation of this offering;                                                 |

| ● | Ordinary Shares underlying                                                                                                   
 warrants issuable to the Company’s chief executive officer to purchase such number of Ordinary Shares equal to two times the 
 respective loan amount due to the Company’s chief executive officer, based on a price per share equal to 75% of the lowest   
 price per Ordinary Share during the first five trading days following the consummation of this offering; and                 |

| ● | Ordinary                                                                                                                              
 Shares underlying warrants issuable to lenders under the 2025 Loan Agreements to purchase such number of Ordinary Shares having a     
 value equal to two times the respective loan amount of each 2025 Loan Agreement owed to such lender, based on a price per share equal 
 to 75% of the lowest price per Ordinary Share during the first five trading days following the consummation of this offering.         |

Unless otherwise indicated, all information in this prospectus assumes or gives effect to:

| ● | no exercise of the Representative’s’ over-allotment option; |

| ● | no exercise of Representative’s W